You are here: Industry Insights > cancer drug

News List

USFDA accepts Merck and Pfizer’s sBLA for Renal Cancer drug biospectrumasia
February 13, 2019
The clinical development program for avelumab, known as JAVELIN, involves at least 30 clinical programs and more than 9,000 patients evaluated across more than 15 different tumor types.
ICR unveils efficacious cancer drug with new mechanism of action pharmaceutical-technology
February 13, 2019
Researchers from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust have announced promising results from a phase I/II into tisotumab vedotin (TV) in patients with one of six, drug-resistant cancers....
Cancer drug with accelerated approval fails Phase III trial europeanpharmaceuticalreview
January 24, 2019
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
Lilly stops promoting cancer drug after shock trial failure pharmaphorum
January 22, 2019
Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine.
Samsung Bioepis secures FDA approval for cancer drug Ontruzant pharmaceutical-technology
January 22, 2019
The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers.....
AZ’s chief medical officer Bohen quits after shake-up pharmaphorum
January 15, 2019
AstraZeneca’s chief medical officer Sean Bohen is to leave the company following its organisational shake-up.
Knight Therapeutics licences cancer drug from Puma Biotechnology pharmaceutical-technology
January 15, 2019
Canada-based Knight Therapeutics signed an exclusive licence agreement with Puma Biotechnology to commercialise Nerlynx (neratinib) medicine in the country.....
Compensating for loss of neurodegenerative disease gene ATM offers insights into cancer drug resistance firstwordpharma
January 09, 2019
Mutations in the ATM gene cause the devastating neurodegenerative and cancer predisposition disease called ataxia-telangiectasia (A-T), and are also associated with various forms of sporadic cancer.
Compensating for loss of neurodegenerative disease gene ATM offers insights into cancer drug resistance firstwordpharma
January 09, 2019
Mutations in the ATM gene cause the devastating neurodegenerative and cancer predisposition disease called ataxia-telangiectasia (A-T), and are also associated with various forms of sporadic cancer.
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development pharmafocusasia
January 09, 2019
Ascentage Pharma Group, Inc., and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies.....

Previous page 1 2 3 4 5 6 Next page